Skip to main content

A Potential Treatment for Pregnant Women with Hyperemesis Gravidarum.

EMERALD Phase 2 Clinical Trial

UPDATE: NGM Bio’s EMERALD Phase 2 Clinical Trial of NGM120 in Hyperemesis Gravidarum is underway in the United Kingdom and Australia

Visit the ISRCTN (United Kingdom) clinical trial listing
Visit the ANZCTR (Australia) clinical trial listing

Scientific Discovery in Understanding HG: Higher Levels of GDF15 Identified as a Risk Factor

Recent research published by an international team that included Marlena Fejzo, Ph.D., Clinical Assistant Professor of Population and Public Health Sciences in the Center for Genetic Epidemiology at the University of Southern California, and Sir Stephen O’Rahilly, M.D. FRS FMedSci, Professor of Clinical Biochemistry and Medicine at the University of Cambridge, found that GDF15 levels increase steadily in early pregnancy and are higher in women who experience nausea and vomiting in pregnancy and hyperemesis. The research uncovered that women with GDF15 genetic variants associated with lower levels of GDF15 in a non-pregnant state are predisposed to hyperemesis.

Chart
Source: Fejzo et al. Nature Communications 2018